n CME : Your SA Journal of CPD - Pharm info

Volume 22, Issue 1
  • ISSN : 0256-2170



Extracted from text ... CHARM PROGRAMME DEMONSTRATES CLEAR BENEFITS OF ATACAND IN THE TREATMENT OF SYMPTOMATIC HEART FAILURE AstraZeneca presented data at the European Society of Cardiology August 2003 annual meeting demonstrating Atacand (candesartan cilexetil) to reduce both cardiovascular deaths as well as hospital admissions for heart failure, across a broad spectrum of patients with chronic heart failure. Atacand is the first angiotensin receptor blocker (ARB) to increase survival in chronic heart failure patients with left ventricular dysfunction, whether or not they are taking an ACE inhibitor. The CHARM programme, which recruited 7 601 patients, is the largest trial programme conducted in heart ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error